Overview
A Study of Escalating Doses of Itacitinib Administered Orally in Patients With Plaque Psoriasis
Status:
Completed
Completed
Trial end date:
2013-02-01
2013-02-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
This is a study of itacitinib in patients with chronic plaque psoriasis. This study will evaluate safety and efficacy parameters of itacitinib.Phase:
Phase 2Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Incyte Corporation
Criteria
Inclusion Criteria:- Subjects with chronic plaque psoriasis aged 18 to 75 who have had insufficient
response to topical agents, and who meet the psoriasis assessment expectations as
defined in the study protocol
Exclusion Criteria:
- Females who are pregnant or breastfeeding
- Men and women who cannot comply with requirements to avoid fathering a child or
becoming pregnant, respectively
- Subjects treated with leflunomide or other biological therapies to treat psoriasis and
all JAK-STAT inhibitors within 12 weeks prior to first dose of study drug